Empowered by global genetic expertise

Our goal is the rapid medical diagnosis of inherited diseases, provided at the earliest possible moment as we turn analytical information into actionable results for physicians, patients and pharmaceutical partners.

Our commitment to the global medical community is an early and precise diagnosis for continuous improvement of therapeutic options for each individual patient.

CentoPortal® – Online ordering portal

From ordering and sample submission through to receipt of the diagnostic report, CentoPortal® is designed to save time and reduce overall workload.

Login   or   Learn more about CentoPortal®

Please note that from June 1, 2017 diagnostic reports will be exclusively provided via CentoPortal®

Expertise you can trust

With CentoNIPT® we offer non-invasive prenatal testing that has the lowest test failure rate among all NIPT technologies on the market.

Request your free starter set now

Our Latest Scientific News

  • Activation of PKC triggers rescue of NPC1 patient specific iPSC derived glial cells from gliosis

    Niemann-Pick disease Type C1 (NPC1) is a rare progressive neurodegenerative disorder caused by mutations in the NPC1 gene. The pathological mechanisms, underlying NPC1 are not yet completely understood. Especially the contribution of glial cells and gliosis to the progression of NPC1, are controversially discussed. As an analysis of affected cells is unfeasible in NPC1-patients, we recently developed an in vitro model system, based on cells derived from NPC1-patient specific iPSCs.

  • Reductions in glucosylsphingosine (lyso-Gb1) in treatment-naïve and previously treated patients receiving velaglucerase alfa for type 1 Gaucher disease

    Gaucher disease (GD), an autosomal recessive lipid storage disorder, arises from mutations in the GBA1 (β-glucocerebrosidase) gene, resulting in glucosylceramide accumulation in tissue macrophages. Lyso-Gb1 (glucosylsphingosine,lyso-GL1), a downstream metabolic product of glucosylceramide, has been identified as a promising biomarker for the diagnosis and onitoring of patients with GD. This retrospective, exploratory analysis of data from phase 3 clinical trials of velaglucerase alfa in patients with type 1 GD evaluated the potential of lyso-Gb1 as a specific and sensitive biomarker for GD.

  • C26-Ceramide as highly sensitive biomarker for the diagnosis of Farber Disease

    Farber disease (FD) is a rare autosomal recessive disease caused by mutations in the acid ceramidase gene (ASAH1). Low ceramidase activity results in the accumulation of fatty substances, mainly ceramides. Hallmark symptoms at clinical level are periarticular nodules, lipogranulomas, swollen and painful joints and a hoarse voice. FD phenotypes are heterogeneous varying from mild to very severe cases, with the patients not surviving past their first year of life. This study has the highest number of enrolled Farber patients and carriers reported to present. Liquid chromatography multiple reaction mass spectrometry (LC/MRM-MS) studies revealed that the ceramide C26:0 and especially its isoform 1 is a highly sensitive and specific biomarker for FD (p < 0.0001). The new biomarker can be determined directly in the dried blood spot extracts with low sample consumption. This allows for easy sample preparation, high reproducibility and use in high throughput screenings.


Dear Prof. Rolfs, ...

I want to thank you again for your support in our activity in rare disease field in Romania. It was a great meeting at Rare Disease Day symposium in Bucharest on 23th February. Centogene team participation contributed immensely to our event. It's amazing how much value you offered to our specialists looking to learn about rare diseases and new genomic technologies. Read more...

Romania, March 2017

Dear colleagues, ...

... the world's best laboratory Centogene!

Ukraine, December 2016

Congratulation ...

... for this success. The secret key of such achievement is the continuous unlimited help, collaboration, dedication and hard work from Centogene team. Special thanks to Daniel and Rami. Looking forward for more publications togother in the near future.

Riyadh, November 2016

I am an experienced neurogeneticist ...

and moved back to Lebanon from the US wanting to make a difference in the diagnosis, care and prevention of recurring neurogenetic disorders in the Lebanese. Alas, I was only partially successful, ... Read more

Lebanon, January 2016

Thank you ...

... very much for your unlimited help and support.

Saudi-Arabia, December 2015

Subscribe to our Newsletter

CENTOGENE is raising venture capital to strengthen its R&D activities and drive its global growth.

Read more

CENTOGENE has recently added the following single gene tests and Next Generation Sequencing panels to its portfolio. CENTOGENE‘s NGS panel composition always...

Read more

An agreement was recently signed for an exciting new collaboration between CENTOGENE, Germany and University Hospital St. Ivan Rilski Sofia, Bulgaria.

Read more

CENTOGENE is proud to announce today our Euro 25 million financing round led by TVM Capital Life Science in cooperation with DPE Deutsche Private Equity,...

Read more

CENTOGENE AG (CENTOGENE) has been working together for years with local, national, and international partners in developing biomarkers to be used in the early...

Read more

Another milestone is reached for our new headquarter in Rostock: Yesterday, we celebrated together with colleagues, friends and partners the Roofing Ceremony....

Read more

CENTOGENE has recently added numerous single gene tests and next generation sequencing (NGS) panels to its portfolio. Our NGS panel compositions always reflect...

Read more

The ‘Rare Disease Day’ is celebrated every February, to help raise awareness and build community for all those affected by rare genetic diseases.

Read more

Our new headquarter in Rostock, CentoNew, is growing rapidly – we started the countdown to our move-in November 2017.

The new headquarter in Rostock will...

Read more